Synergistic antiproliferative effects of combined γ-tocotrienol and PPAR γ antagonist treatment are mediated through PPAR γ-independent mechanisms in breast cancer cells

PPAR Research

Volumn 2014, Issue , 2014, Pages

  Malaviya, Abhita ^a   Sylvester, Paul W ^a  

^a UNIVERSITY OF LOUISIANA AT MONROE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 5 NITRO N (4 PYRIDYL)BENZAMIDE; 2 CHLORO 5 NITROBENZANILIDE; GAMMA TOCOTRIENOL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PROSTAGLANDIN D2; PROSTAGLANDIN SYNTHASE; ROSIGLITAZONE; TROGLITAZONE;

ANIMAL CELL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER; BREAST CELL; CANCER CELL; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE PROGRESSION; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; WESTERN BLOTTING;

EID: 84896914635     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2014/439146     Document Type: Article

References (53)

1. McIntyre B. S., Briski K. P., Tirmenstein M. A., Fariss M. W., Gapor A., Sylvester P. W., Antiproliferative and apoptotic effects of tocopherols and tocotrienols on normal mouse mammary epithelial cells. Lipids 2000 35 2 171 180 2-s2.0-0034034058 (Pubitemid 30183648)
2. Mcintyre B. S., Briski K. P., Gapor A., Sylvester P. W., Antiproliferative and apoptotic effects of tocopherols and tocotrienols on preneoplastic and neoplastic mouse mammary epithelial cells. Experimental Biology and Medicine 2000 224 4 292 301 2-s2.0-0033872034 (Pubitemid 30643508)
3. Schneider C., Chemistry and biology of vitamin E. Molecular Nutrition & Food Research 2005 49 7 30 (Pubitemid 40178942)
4. Sylvester P. W., Shah S. J., Mechanisms mediating the antiproliferative and apoptotic effects of vitamin E in mammary cancer cells. Frontiers in Bioscience 2005 10 699 709 2-s2.0-20144385472
5. Samant G. V., Sylvester P. W., γ -tocotrienol inhibits ErbB3-dependent PI3K/Akt mitogenic signalling in neoplastic mammary epithelial cells. Cell Proliferation 2006 39 6 563 574 2-s2.0-33751061128 10.1111/j.1365-2184.2006.00412.x (Pubitemid 44760206)
6. Bachawal S. V., Wali V. B., Sylvester P. W., Enhanced antiproliferative and apoptotic response to combined treatment of γ -tocotrienol with erlotinib or gefitinib in mammary tumor cells. BMC Cancer 2010 10, article 84 2-s2.0-77950448927 10.1186/1471-2407-10-84
7. Fang F., Kang Z., Wong C., Vitamin E tocotrienols improve insulin sensitivity through activating peroxisome proliferator-activated receptors. Molecular Nutrition and Food Research 2010 54 3 345 352 2-s2.0-77649303444 10.1002/mnfr.200900119
8. Campbell S. E., Rudder B., Phillips R. B., Whaley S. G., Stimmel J. B., Leesnitzer L. M., Lightner J., Dessus-Babus S., Duffourc M., Stone W. L., Menter D. G., Newman R. A., Yang P., Aggarwal B. B., Krishnan K., γ -tocotrienol induces growth arrest through a novel pathway with TGF β 2 in prostate cancer. Free Radical Biology and Medicine 2011 50 10 1344 1354 2-s2.0-79955476952 10.1016/j.freeradbiomed.2011.02.007
9. Malaviya A., Sylvester P. W., Mechanisms mediating the effects of gamma-tocotrienol when used in combination with PPARgamma agonists or antagonists on MCF-7 and MDA-MB-231 breast cancer cells. International Journal of Breast Cancer 2013 2013 101705 10.1155/2013/101705
10. Rosen E. D., Spiegelman B. M., PPAR γ: a nuclear regulator of metabolism, differentiation, and cell growth. Journal of Biological Chemistry 2001 276 41 37731 37734 2-s2.0-0035851187
11. Wahli W., Braissant O., Desvergne B., Peroxisome proliferator activated receptors: transcriptional regulators of adipogenesis, lipid metabolism and more. Chemistry and Biology 1995 2 5 261 266 2-s2.0-0029294531 10.1016/1074-5521(95)90045-4
12. Kliewer S. A., Lenhard J. M., Willson T. M., Patel I., Morris D. C., Lehmann J. M., A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell 1995 83 5 813 819 2-s2.0-0028972026 (Pubitemid 3006325)
13. Forman B. M., Tontonoz P., Chen J., Brun R. P., Spiegelman B. M., Evans R. M., 15-deoxy-Δ12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR γ Cell 1995 83 5 803 812 2-s2.0-0028972025 (Pubitemid 3006324)
14. Urade Y., Eguchi N., Lipocalin-type and hematopoietic prostaglandin D synthases as a novel example of functional convergence. Prostaglandins and Other Lipid Mediators 2002 68-69 375 382 2-s2.0-0036669560 10.1016/S0090-6980(02) 00042-4 (Pubitemid 35247408)
15. Chinery R., Coffey R. J., Graves-Deal R., Kirkland S. C., Sanchez S. C., Zackert W. E., Oates J. A., Morrow J. D., Prostaglandin J2 and 15-deoxy-Δ12,14-prostaglandin J2 induce proliferation of cyclooxygenase-depleted colorectal cancer cells. Cancer Research 1999 59 11 2739 2746 2-s2.0-0033137322 (Pubitemid 29269124)
16. Badawi A. F., Badr M. Z., Chemoprevention of breast cancer by targeting cyclooxygenase-2 and peroxisome proliferator-activated receptor-gamma (Review). International Journal of Oncology 2002 20 6 1109 1122 2-s2.0-0036618210
17. Chawla A., Barak Y., Nagy L., Liao D., Tontonoz P., Evans R. M., PPAR- γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nature Medicine 2001 7 1 48 52 2-s2.0-0035132330 10.1038/83336 (Pubitemid 32095641)
18. Eibl G., The role of PPAR- γ and its interaction with COX-2 in pancreatic cancer. PPAR Research 2008 2008 2-s2.0-47349128912 10.1155/2008/326915 326915 (Pubitemid 352000624)
19. Clay C. E., Monjazeb A., Thorburn J., Chilton F. H., High K. P., 15-Deoxy-Δ12,14-prostaglandin J2-induced apoptosis does not require PPAR γ in breast cancer cells. Journal of Lipid Research 2002 43 11 1818 1828 2-s2.0-0036847134 10.1194/jlr.M200224-JLR200 (Pubitemid 35315799)
20. Li H., Narahara H., 15-deoxy-delta(12,14)-prostaglandin J(2) induces growth inhibition, cell cycle arrest and apoptosis in human endometrial cancer cell lines. International Journal of Molecular Medicine 2013 31 778 788
21. Wu S.-J., Liu P.-L., Ng L.-T., Tocotrienol-rich fraction of palm oil exhibits anti-inflammatory property by suppressing the expression of inflammatory mediators in human monocytic cells. Molecular Nutrition and Food Research 2008 52 8 921 929 2-s2.0-54549094783 10.1002/mnfr.200700418
22. Shirode A. B., Sylvester P. W., Synergistic anticancer effects of combined γ -tocotrienol and celecoxib treatment are associated with suppression in Akt and NF B signaling. Biomedicine and Pharmacotherapy 2010 64 5 327 332 2-s2.0-77953285620 10.1016/j.biopha.2009.09.018
23. Shirode A. B., Sylvester P. W., Mechanisms mediating the synergistic anticancer effects of combined γ -tocotrienol and celecoxib treatment. Journal of Bioanalysis and Biomedicine 2011 3 1 1 7 2-s2.0-79951969599 10.4172/1948-593X.1000036
24. Zaytseva Y. Y., Wallis N. K., Southard R. C., Kilgore M. W., The PPAR γ antagonist T0070907 suppresses breast cancer cell proliferation and motility via both PPAR γ -dependent and -independent mechanisms. Anticancer Research 2011 31 3 813 823 2-s2.0-79956134760
25. Sikka S., Chen L., Sethi G., Kumar A. P., Targeting PPARgamma signaling cascade for the prevention and treatment of prostate cancer. PPAR Research 2012 2012 14 968040 10.1155/2012/968040
26. Anderson L. W., Danielson K. G., Hosick H. L., New cell line. Epithelial cell line and subline established from premalignant mouse mammary tissue. In Vitro 1979 15 11 841 843 2-s2.0-0018540679
27. Danielson K. G., Anderson L. W., Hosick H. L., Selection and characterization in culture of mammary tumor cells with distinctive growth properties in vivo. Cancer Research 1980 40 6 1812 1819 2-s2.0-0018897883 (Pubitemid 10116096)
28. Laemmli U. K., Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970 227 5259 680 685 2-s2.0-0014949207 10.1038/227680a0
29. Sylvester P. W., Birkenfeld H. P., Hosick H. L., Briski K. P., Fatty acid modulation of epidermal growth factor-induced mouse mammary epithelial cell proliferation in vitro. Experimental Cell Research 1994 214 1 145 153 2-s2.0-0028070098 10.1006/excr.1994.1243 (Pubitemid 24302387)
30. Towbin H., Staehelin T., Gordon J., Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proceedings of the National Academy of Sciences of the United States of America 1979 76 9 4350 4354 2-s2.0-0009482260 (Pubitemid 9256559)
31. Kim H.-H., Vijapurkar U., Hellyer N. J., Bravo D., Koland J. G., Signal transduction by epidermal growth factor and heregulin via the kinase-deficient ErbB3 protein. Biochemical Journal 1998 334 1, part 1 189 195 2-s2.0-0032529048 (Pubitemid 28420988)
32. Tallarida R. J., Drug synergism: its detection and applications. Journal of Pharmacology and Experimental Therapeutics 2001 298 3 865 872 2-s2.0-0034889197 (Pubitemid 32761897)
33. Shen D., Deng C., Zhang M., Peroxisome proliferator-activated receptor γ agonists inhibit the proliferation and invasion of human colon cancer cells. Postgraduate Medical Journal 2007 83 980 414 419 2-s2.0-34250773317 10.1136/pmj.2006.052761 (Pubitemid 46960828)
34. Sylvester P. W., Wali V. B., Bachawal S. V., Shirode A. B., Ayoub N. M., Akl M. R., Tocotrienol combination therapy results in synergistic anticancer response. Frontiers in Bioscience 2011 16 7 3183 3195 2-s2.0-79959562482 10.2741/3905
35. Nesaretnam K., Guthrie N., Chambers A. F., Carroll K. K., Effect of tocotrienols on the growth of a human breast cancer cell line in culture. Lipids 1995 30 12 1139 1143 2-s2.0-0028810946 10.1007/BF02536615
36. Nesaretnam K., Stephen R., Dils R., Darbre P., Tocotrienols inhibit the growth of human breast cancer cells irrespective of estrogen receptor status. Lipids 1998 33 5 461 469 2-s2.0-0031744718 10.1007/s11745-998-0229-3 (Pubitemid 28261949)
37. Wang X., Southard R. C., Kilgore M. W., The increased expression of peroxisome proliferator-activated receptor- γ 1 in human breast cancer is mediated by selective promoter usage. Cancer Research 2004 64 16 5592 5596 2-s2.0-4143115845 10.1158/0008-5472.CAN-04-0043 (Pubitemid 39095554)
38. Zaytseva Y. Y., Wang X., Southard R. C., Wallis N. K., Kilgore M. W., Down-regulation of PPARgamma1 suppresses cell growth and induces apoptosis in MCF-7 breast cancer cells. Molecular Cancer 2008 7, article 90 2-s2.0-58149528272 10.1186/1476-4598-7-90
39. Subbarayan V., Xu X.-C., Kim J., Yang P., Hoque A., Sabichi A. L., Llansa N., Mendoza G., Logothetis C. J., Newman R. A., Lippman S. M., Menter D. G., Inverse relationship between 15-lipoxygenase-2 and PPAR- γ gene expression in normal epithelia compared with tumor epithelia. Neoplasia 2005 7 3 280 293 2-s2.0-20144364754 10.1593/neo.04457 (Pubitemid 40411640)
40. Lea M. A., Sura M., Desbordes C., Inhibition of cell proliferation by potential Peroxisome Proliferator-Activated Receptor (PPAR) gamma agonists and antagonists. Anticancer Research 2004 24 5 2765 2771 2-s2.0-6444238770 (Pubitemid 39407154)
41. Burton J. D., Goldenberg D. M., Blumenthal R. D., Potential of peroxisome proliferator-activated receptor gamma antagonist compounds as therapeutic agents for a wide range of cancer types. PPAR Research 2008 2008 7 2-s2.0-53149098608 10.1155/2008/494161 494161
42. Reddy J. K., Viswakarma N., Jia Y., Bai L., Vluggens A., Borensztajn J., Xu J., Coactivators in PPAR-regulated gene expression. PPAR Research 2010 2010 21 2-s2.0-77956835278 10.1155/2010/250126 250126
43. Uefuji K., Ichikura T., Mochizuki H., Expression of cyclooxygenase-2 in human gastric adenomas and adenocarcinomas. Journal of Surgical Oncology 2001 76 26 30 (Pubitemid 32128359)
44. Tucker O. N., Dannenberg A. J., Yang E. K., Zhang F., Teng L., Daly J. M., Soslow R. A., Masferrer J. L., Woerner B. M., Koki A. T., Fahey T. J. III, Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Research 1999 59 5 987 990 2-s2.0-0033106051 (Pubitemid 29135954)
45. Kulkarni S., Rader J. S., Zhang F., Liapis H., Koki A. T., Masferrer J. L., Subbaramaiah K., Dannenberg A. J., Cyclooxygenase-2 is overexpressed in human cervical cancer. Clinical Cancer Research 2001 7 2 429 434 2-s2.0-0035126879 (Pubitemid 32183049)
46. Davies N. M., Jamali F., COX-2 selective inhibitors cardiac toxicity: getting to the heart of the matter. Journal of Pharmacy and Pharmaceutical Sciences 2004 7 3 332 336 2-s2.0-16244365087 (Pubitemid 41528882)
47. Fujimori K., Aritake K., Urade Y., Enhancement of prostaglandin D2 production through cyclooxygenase-2 and lipocalin-type prostaglandin D synthase by upstream stimulatory factor 1 in human brain-derived TE671 cells under serum starvation. Gene 2008 426 1-2 72 80 2-s2.0-54049116576 10.1016/j.gene.2008.08. 023
48. Masamha C. P., Benbrook D. M., Cyclin D1 degradation is sufficient to induce G1 cell cycle arrest despite constitutive expression of cyclin E2 in ovarian cancer cells. Cancer Research 2009 69 16 6565 6572 2-s2.0-69249155033 10.1158/0008-5472.CAN-09-0913
49. Samant G. V., Wali V. B., Sylvester P. W., Anti-proliferative effects of γ -tocotrienol on mammary tumour cells are associated with suppression of cell cycle progression. Cell Proliferation 2010 43 1 77 83 2-s2.0-73349116547 10.1111/j.1365-2184.2009.00657.x
50. Weng J.-R., Chen C.-Y., Pinzone J. J., Ringel M. D., Chen C.-S., Beyond peroxisome proliferator-activated receptor γ signaling: the multi-facets of the antitumor effect of thiazolidinediones. Endocrine-Related Cancer 2006 13 2 401 413 2-s2.0-33745113772 10.1677/erc.1.01182 (Pubitemid 43886665)
51. Suzuki H., Sato K., Yoshizumi N., Nishiya I., Inhibition of growth of human endometrial adenocarcinoma cells in vitro treated with prostaglandin F2 alpha, E2, D2 and J2. Nippon Naibunpi Gakkai zasshi 1986 62 8 857 866 2-s2.0-0023053673
52. Yoshida T., Ohki S., Kanazawa M., Mizunuma H., Kikuchi Y., Satoh H., Andoh Y., Tsuchiya A., Abe R., Inhibitory effects of prostaglandin D2 against the proliferation of human colon cancer cell lines and hepatic metastasis from colorectal cancer. Surgery Today 1998 28 7 740 745 2-s2.0-0031826157 10.1007/s005950050219 (Pubitemid 28341300)
53. Scher J. U., Pillinger M. H., 15d-PGJ2: the anti-inflammatory prostaglandin? Clinical Immunology 2005 114 2 100 109 2-s2.0-11444261543 10.1016/j.clim.2004.09.008 (Pubitemid 40082375)